Since anti-β-catenin drug discovery is a timely concept, and models like DEN/PB may be of essence in testing anti-β-catenin therapies, our studies demonstrate the suitability of assessing serum Lect2 levels in such models to monitor tumor response to experimental therapies. The gene discussed is LECT2; the disease is neoplasm.